Position history for RA CAPITAL MANAGEMENT, L.P.'s holdings in 4D MOLECULAR THERAPEUTICS IN
RA CAPITAL MANAGEMENT, L.P. holds 5M shares of FDMT (4D MOLECULAR THERAPEUTICS IN), worth $47M as of 2026-Q1. The position was decreased (-10.7% shares). FDMT represents 0.5% of RA CAPITAL MANAGEMENT, L.P.'s portfolio.
Current Value
$47M
Current Shares
5M
Total Value Change
-$60M
Total Shares Change
-48,432
Other major holders of FDMT: UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC, VIKING GLOBAL INVESTORS LP
Decreased |
| 5M |
-10.7% |
| $47M |
| 0.5% |
| $8.46 |
0 |
| 2025-Q4 | Increased | 5.7M | +23.9% | $42.4M | 0.4% | $7.58 | 42 |
| 2025-Q3 | Unchanged | 4.6M | 0.0% | $39.7M | 0.5% | $8.35 | 0 |
| 2025-Q2 | Unchanged | 4.6M | 0.0% | $16.9M | 0.3% | $3.84 | 0 |
| 2025-Q1 | Unchanged | 4.6M | 0.0% | $14.7M | 0.2% | $3.63 | 0 |
| 2024-Q4 | Decreased | 4.6M | -10.5% | $25.4M | 0.3% | $5.30 | 0 |
| 2024-Q3 | Unchanged | 5.1M | 0.0% | $55.1M | 0.6% | $10.83 | 0 |
| 2024-Q2 | Increased | 5.1M | +0.9% | $107M | 1.4% | $20.99 | 48 |